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Abstract: A critical role of Cyclophilins, mostly Cyclophilin A (CyPA), in the replication 
of HCV is supported by a growing body of in vitro and in vivo evidence. CyPA probably 
interacts directly with nonstructural protein 5A to exert its effect, through its peptidyl-prolyl 
isomerase activity, on maintaining the proper structure and function of the HCV replicase. 
The major proline substrates are located in domain II of NS5A, centered around a “DY” 
dipeptide motif that regulates CyPA dependence and CsA resistance. Importantly, 
Cyclosporine A derivatives that lack immunosuppressive function efficiently block the 
CyPA-NS5A interaction and inhibit HCV in cell culture, an animal model, and human trials. 
Given the high genetic barrier to development of resistance and the distinctness of their 
mechanism from that of either the current standard of care or any specifically targeted 
antiviral therapy for HCV (STAT-C), CyP inhibitors hold promise as a novel class of anti-
HCV therapy. 
Keywords:  Cyclophilins; Cyclosporine A; immunosuppression; nonstructural protein 
5A/5B; HCV replication 
 
1. Introduction 
Like all obligate intracellular parasites, viruses depend upon their host for survival and 
reproduction. Certain host proteins therefore assume, in addition to their normal cellular function, the 
unbecoming title of “cellular cofactors” for viral infection. In the majority of cases these proteins are 
simply too important to the host to be considered practical drug targets. Occasionally though, an 
opportunity for targeting a cellular cofactor would emerge, most often as a result of functional 
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redundancy at the cellular but not the viral level. For RNA viruses with high mutation rates and great 
diversity, directing intervention at a cellular cofactor may offer the advantage of higher genetic barrier 
to development of resistance. A prominent success story for this strategy is the FDA approval of an 
anti-HIV drug that targets the C-C chemokine receptor type 5 (CCR5)  [1]. 
Hepatitis C virus (HCV) infection tends to become chronic in most patients and can lead to liver 
fibrosis, cirrhosis, and hepatocellular carcinoma. The current treatment of HCV infection is not 
optimal, mainly as a result of resistance to interferon (IFN) in a large percentage of patients, especially 
those infected with genotype 1. New classes of anti-HCV drugs are being pursued by virtually all 
major pharmaceutical companies. In addition to the specifically targeted antiviral therapy for HCV 
(STAT-C), whose target is viral proteins, small-molecule compounds that inhibit an essential cellular 
cofactor, Cyclophilin A (CyPA), have also generated considerable interests because of their promising 
efficacy results in both preclinical and clinical studies. Here I summarize current understanding of 
CyPA’s role in the HCV life cycle and progress of the preclinical and clinical development of CyP 
inhibitors (CPIs) as anti-HCV drug candidates. I will also discuss potential mechanisms of resistance 
to CPIs, on the basis of research carried out in cell-culture systems. 
2. Cyclosporine A and HCV infection 
Cyclophilins are high-affinity protein ligands of Cyclosporine A (CsA), a compound originally 
isolated from the soil fungus Tolypocladium inflatum and an immunosuppressive and anti-
inflammatory drug approved for use in organ-transplant patients. Another commonly used 
immunosuppressive compound, FK506 (Tacrolimus), binds to a different group of proteins, called 
FK506-binding proteins. Despite having distinct individual structures for both the compounds and the 
proteins, the CsA-CyPA complex and that of FK506 with the FK506-binding proteins, through a 
composite surface, bind to a common target, calcineurin, and block its phosphatase activity, which is 
critical for the expression of the cytokine T-cell activation  [2]. The earliest indication that CsA might 
suppress HCV replication was reported even before the virus was cloned and named as HCV. In two 
experimentally infected chimpanzees, the histometric scores representing ultrastructural changes in 
hepatocytes improved with intravenous administration of CsA  [3]. The authors speculated that CsA 
had inhibited the proliferation of HCV, which was still identified as non-A, non-B type 1 hepatitis 
virus (NANBHV)  [4]. Fifteen years later, CsA was demonstrated to inhibit HCV replication directly 
in a cell culture–based replicon system  [5,6]. The finding that CsA’s anti-HCV effect was independent 
of its immunosuppressive function was promising, as the idea of treating a viral infection with an 
immunosuppressive drug seemed counterintuitive. In addition, CsA's inhibition of HCV through a 
mechanism distinct from that of IFN raised hope of a synergy with IFN in a combination treatment. 
In HCV-infected liver-transplant patients, benefits of CsA over FK506, which does not inhibit 
HCV in vitro, in alleviating the severity of recurrent HCV have been supported by some studies but 
disputed by others  [7-13]. On the other hand, combination of IFN and CsA was clearly more effective 
in achieving sustained virological response than was IFN monotherapy, especially in patients with 
genotype 1 virus, high viral load, or both  [14,15]. More recently, several CsA derivatives that are 
devoid of immunusuppresive function have been demonstrated to be efficacious in inhibiting HCV 
replication in both preclinical and clinical studies  [16-22]. The leading compound of this class, Debio-Viruses 2010, 2                                       
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025, is currently being tested in a phase IIb human trial. A number of reasons may account for the 
failure of CsA to show any anti-HCV benefits in certain transplant patients. First, the immune 
functions of these patients are suppressed by CsA and the antiviral effect alone may not be enough to 
suppress the virus without the help of the immune system; second, the standard dosage of CsA used in 
these transplant patients may be low as far as the anti-HCV function is concerned. Debio-025, which is 
already more potent than CsA at inhibiting HCV replication in vitro, was given at 600–1200 mg BID, 
whereas the daily dosage of CsA in the liver-transplant patients was 4-5 times lower.  
3. Cyclophilin A as an essential HCV cofactor 
In vitro studies of CsA derivatives revealed a correlation between viral inhibition and CyP 
binding  [20,23], suggesting that one or more CyPs are the direct targets of CsA’s inhibitory action on 
HCV replication. Despite early suggestions that CyPB and/or CyPC plays an important role in HCV 
replication and that different genotypes of HCV require different CyPs   [23,24], results from the 
author’s lab first indicated a universal and acute requirement for CyPA, but not CyPB or CyPC, for the 
replication of genotypes 1a, 1b, and 2a  [25]. That CyPA is the most important of the CyP isoforms for 
HCV replication was quickly confirmed by more independent studies  [26-29]. Considering the drastic 
difference (at least 10-fold) between the expression level of CyPA and that of the other CyP isoforms 
in liver cells  [25], it is perhaps not surprising that the most abundant form, CyPA, is also the most 
critical for HCV replication. Previous work has shown that, although both CyPA and CyPB can bind to 
HIV Gag protein in vitro  [30], knocking out CyPA alone in a T-cell line was able to completely block 
infection by HIV  [31], which also requires CyPA as an essential cofactor to infect these cells. Note 
that other CyPs, having structures highly similar to that of CyPA  [32-34], are probably able to bind to 
HCV protein in vitro when large amounts of recombinant CyP proteins are used   [23,35-37]. 
Correspondingly, these additional CyP isoforms may contribute to HCV replication either when they 
are overexpressed or when CyPA level is reduced by RNA interference. 
Following the identification of CyPA as a high-affinity intracellular ligand for CsA by 
Handschumacher and colleagues  [38], two independent studies assigned the peptidyl-prolyl isomerase 
(PPIase) activity that they were tracking to CyPA by purifying the in vitro activity that catalyzed the 
cis-trans isomerization of Xaa-Pro amide bonds  [39,40]. Interestingly, although CsA-binding potently 
inhibits the PPIase activity of CyPA, the isomerase activity appears to be dispensable for calcineurin 
binding and immune suppression. Several point mutations (R55A, F60A, and H126Q) in the active site 
of CyPA reduced PPIase activity by 190- to 1000-fold on a peptide substrate, yet retained CsA-binding 
and calcineurin inhibition  [41]. The same mutations have also been shown to be crippling for CyPA’s 
HCV cofactor function in cDNA rescue experiments  [26,27,42], suggesting that the PPIase activity is 
required for HCV replication.  
For HIV infection, CyPA recognizes a single proline residue on the capsid protein to which it binds 
in a CsA-sensitive manner  [43], but the potential target of CyPA’s PPIase activity relevant for HCV 
replication is probably not restricted to a particular proline. In fact, several HCV proteins (NS5A, 
NS5B, and NS2) have been suggested to be targets of CyPA’s cofactor function  [23,28,35,37,44]. In 
particular, a CsA-sensitive interaction between NS5A and CyPA can be demonstrated in vitro  [44-46], 
and the CyPA binding site has been mapped, at least in part, to the proline-rich domain II of NS5A. Viruses 2010, 2                                       
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Nuclear magnetic resonance analysis revealed that even within domain II, multiple prolines are likely 
to be involved in CyPA binding and isomerization  [44]. 
Precisely why HCV needs CyPA to replicate has not yet been resolved. One proposed function of 
CyPA is to ensure the integrity of the viral replication complexes (RC)  [42]. Although the majority of 
the CyPA protein is found to be cytosolic, a small percentage cofractionates with intracellular 
membranes. CsA treatment disrupts this membrane association of CyPA  [42]. In addition, a loss of 
membrane-protected and protease-resistant NS5B can be observed in replicon cells treated with CsA, 
suggesting CyPA’s action, either through NS5A or directly, is required for the proper incorporation of 
NS5B into the membrane-enclosed RC. A subsequent study independently confirmed the CsA-
sensitive association of CyPA with cellular membranes but argued against a role for CyPA in the RC 
incorporation of NS5A or NS5B  [47]. Understanding more details of the RC assembly process and the 
mechanism of selective incorporation of only a small percentage of NS proteins  [48] might require a 
biochemically traceable in vitro replication assay. 
4. Inhibition of HCV replication by cyclophilin inhibitors 
CsA derivatives that lack the immunosuppressive function have been shown to inhibit HCV 
replication in cell-culture models  [16,20,22,24,49]. The structures of four such compounds, Debio-
025, NIM 811, SCY-635, and CsD, are shown in Figure 1A. The CyP-binding surface of CsA, made 
up of residues 1, 2, 3, 9, 10, and 11, appears to conserved, as all the derivatives can bind CyPs and 
inhibit their PPIase activity. On the other hand, none of these derivatives could form a stable tertiary 
complex with CyPA and calcineurin, as CsA can; this explains their inability to suppress T-cell 
activation and IL-2 production. Residues 4 through 7 of CsA are important for calcineurin binding  [2]. 
In particular, the N-methyl-Leu side chain at position 4 of CsA appears to be critical, as it occupies the 
hydrophobic pocket of the calcineurin protein  [50]. With the exception of CsD, the CsA derivatives all 
differ from CsA and from each other at position 4. The N-ethyl-Val of Debio-025 is too short to enter 
the calcineurin pocket   [50], and the side-chain modifications on NIM811 (in which a sec-butyl 
replaces an isobutyl group) and SCY-635 (in which a hydroxyl is substituted at the γ-carbon of N-
methyl-Leu) probably affect calcineurin binding through steric hindrance. The reason for the reduced 
immunosuppressive function of CsD is not yet understood  [51]. 
Debio-025 (also named Alisporivir) is a synthetic derivative of CsA that has chemical 
modifications at positions 3 and 4. These changes appear not only to abolish its immunosuppressive 
function but also to increase its inhibitory effect on CyP, as suggested by an approximately 10-fold 
lower EC50 against HCV compared to that of CsA  [16]. The anti-HCV activity of Debio-025 has been 
extensively studied in cell culture   [16], mice   [17], and humans   [19,52]. In cell-culture systems, 
Debio-025 efficiently inhibited replication of both subgenomic replicons and a full-length infectious 
virus; it was also able to clear replicon cells of persistent replication   [18], much the same way 
interferon did in these cells  [53]. In a human liver SCID/uPA mouse model, where the mouse liver has 
been repopulated by transplanted human hepatocytes that can then be infected with HCV patient 
serum  [54], the combination of Debio-025 (100 mg/kg/day, orally) with pegylated interferon-α (peg-
IFN) (30 µg/kg subcutaneously twice weekly) resulted in 100-fold decrease in serum HCV RNA levels 
while peg-IFN alone only resulted in a 10-fold decrease  [17]. Similar results were obtained with Viruses 2010, 2                                       
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chimeric mice infected with either genotype (GT) 1a or 1b HCV. Curiously, Debio-025 alone had no 
effect on HCV replication in this setting. In addition, because the mice that received the combination 
of CsA (100 mg/kg/day orally) and peg-IFN all died with 4 days of the treatment, a direct comparison 
of Debio-025 and CsA in this model was not available.  
Figure 1. Structures of CPIs that inhibit HCV replication. (A) CsA derivatives that lack 
the immunosuppressive function. (B) Sanglifehrin A, a CyP-binder with a structure 
unrelated to CsA. 
 
 
In human trials, the antiviral effect of Debio-025 was first evaluated in a small group of HIV/HCV-
infected patients as a monotherapy  [52]. The 19 co-infected patients were divided into a placebo 
group (n = 3) and a Debio-025 group (n = 16) which received 1200 mg of Debio-025 twice daily for 
14 days. At the end of the study, the mean HCV viral load was decreased by 3.6 logs in the Debio-025 
group but only by 0.7 log in the placebo group (p < 0.0001). The anti-HIV effect was less impressive 
with a 1.1-log decrease of HIV RNA copies/mL in the Debio-025 group. With the control group also 
showing a 0.5-log reduction, no significant difference between compound and placebo could be 
demonstrated in terms of HIV inhibition in this limited trial. Given the promising results regarding 
HCV infection, however, a larger, phase IIa clinical trial was then carried out to determine the efficacy 
and safety of Debio-025 in combination with peg-IFNα-2a   [19]. Ninety patients were randomly 
divided into five groups and treated for 29 days with the following regimens: peg-IFN with placebo; Viruses 2010, 2                                       
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peg-IFN with 200 mg/day Debio-025; peg-IFN with 600 mg/day Debio-025; peg-IFN with 1000 
mg/day Debio-025; and 1000 mg/day Debio-025 only. The two combination groups with higher 
Debio-025 concentrations achieved significantly greater reduction of HCV RNA (4.6 logs for the   
600-mg combination and 4.8 logs for the 1000-mg combination) than either of the monotherapies 
(2.5 logs for peg-IFN monotherapy and 2.2 logs for the Debio-025 monotherapy). In addition, viral 
load was undetectable in 66% of the patients in the 1000-mg combination group but in only 25% of the 
patients treated with either of the monotherapies. Currently, a phase IIb trial is underway that will 
examine the safety and efficacy of Debio-025 in combination with the standard of care for HCV: peg-
IFNα plus ribavirin. The study is being conducted in treatment-naïve patients infected by the most 
prevalent genotype (GT1), and results of the trial are not yet available as of this writing. 
NIM811 was the first CsA derivative lacking immunosuppressive function to be synthesized, albeit 
as an inhibitor for HIV infection  [55]. Like that of Debio-025, the higher CyP-binding affinity of 
NIM811  [49] is correlated with a more potent anti-HCV activity in the replicon system   [20]. 
Importantly, combining NIM811 with NS3-4A protease or NS5B polymerase inhibitors not only 
resulted in an additive inhibition of viral replication but also suppressed the emergence of resistance to 
the viral enzyme inhibitors  [21]. 
SCY-635 is another CsA-based CyP inhibitor with modifications at positions 3 and 4  [22]. It 
inhibited the PPIase activity of CyPA in vitro and suppressed HCV replication in replicon cells. 
Importantly, SCY-635 exhibited no inhibition of calcineurin phosphatase activity when complexed 
with CyPA at 2 µM, a concentration 20 times the EC50 for replicon inhibition in vitro. In a phase 1b 
monotherapy trial of GT1-infected patients, the treatment groups were given daily doses of 300, 600, 
and 900 mg for 15 days, either once daily or in divided doses three times per day. The highest dose of 
SCY-635 produced significant antiviral activity and resulted in a viral load reduction of 2.2 logs. Of 
the 20 subjects who were given SCY-635 three times daily, one achieved undetectable RNA levels at 
day 15  [56]. 
CsD is a cyclosporine analogue that has a valine in the place of an aminobutyric acid at position 
2 of CsA  [57]. Although it could inhibit HCV replicon in vitro  [24], it does not appear to be as potent 
as the other derivatives and may have retained part of CsA’s immunosuppressive function  [51]. 
In addition to CsA-derived inhibitors, CyPA inhibitors that are structurally distinct from CsA, such 
as the macrocyclic compound Sanglifehrin A (SFA) produced by the actinomycetes
  strain 
Streptomyces A92-308110 (Figure 1b), can also suppress HCV replication  [58,59], further validating 
the critical role of CyPA in HCV life cycle. The immunosuppressive function of Sanglifehrin A, which 
appears unrelated to calcineurin inhibition  [60,61], will likely prevent the direct use of the unmodified 
compound as an anti-HCV drug. Nevertheless, these data suggest the feasibility of developing 
chemically independent CyPA inhibitors for HCV suppression  [59]. 
5. Viral resistance to CPIs 
One of the theoretical advantages of targeting host cofactors rather than viral agents is the 
presumed higher genetic barrier to development of resistance. Mathematic modeling of viral dynamics 
suggests that both single and double mutations exist in the HCV population before treatment and that 
at least one more mutation is likely to emerge during treatment  [62]. On the basis of this calculation, Viruses 2010, 2                                       
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for small molecule inhibitors whose targets are viral enzymes such as NS3/4A protease or the NS5B 
polymerase, resistant viruses are expected to arise rapidly during therapy unless combination therapies 
with genetic barriers of four or more mutations are used. Several labs have characterized HCV 
resistance to CsA in vitro, using either subgenomic replicons  [26,35,37,58,59] or, in a more recent 
study, JFH-1 full-length virus   [63]. Taking advantage of a sortable replicon that contains a GFP 
reporter inserted into the NS5A gene  [64,65], Robida et al. used antibiotic selection and live cell 
sorting to isolate replicon cells that were approximately 17-fold more resistant to CsA than genotype- 
and reporter-matched wild-type replicon. As expected, these cells were also cross-resistant to Debio-
025 and NIM 811 (Tang H, unpublished results). Because these compounds inhibit a cellular target, 
determining the relative contributions of cellular and viral mutations to the observed drug resistance 
exhibited by the selected replicon cells was important. By separating viral RNA and host cells of the 
resistant cell line and remixing them with naïve cells and wild-type replicon RNA, 
respectively  [37,66], these authors demonstrated that mutations in viral RNAs, but not changes in the 
host cell, are responsible for CsA resistance. 
Mutations in both NS5B and NS5A appear to contribute to CsA resistance, and early mapping 
studies generated a rather scattered mutation profile  [26,35,37], suggesting that mutations in more 
than one site or even in more than one protein may be necessary to confer the full-level of resistance 
conferred by the selected replicon. Although this idea is consistent with a high genetic barrier to 
resistance, as supported by the lack of in vivo resistance so far, more recent results do point to a 
specific “Asp-Tyr” dipeptide motif (D320-Y321 in GT1 or D316-Y317 in GT2a) in the domain II of 
NS5A as a major regulator of HCV’s susceptibility to CsA and other CPIs, at least in 
vitro   [45,58,59,63,67]. Mutation of Aspartate into Glutamate or of Tyrosine into Asparagine 
individually conferred CsA resistance in replicons of various genotypes, and the combination the 
D316E and Y317N mutations in a J6/JFH-1 full-length genome resulted in a virus that replicated 
several fold better in CyPA-knockdown cells than in control cells  [63]. These results, together with 
the biophysical  [44] and functional  [63] mapping of the proline substrates to this segment of domain 
II, strongly support a major role of DY motif–containing peptide in determining HCV’s susceptibility 
to CPIs. Interestingly, although Sanglifehrin A treatment also selected for the D320E mutation  [59], 
the highly potent NS5A inhibitor BMS-790052 selected for resistance mutations in the domain I of 
NS5A  [68], suggesting that the BMS compound and CPIs use distinct mechanisms to inhibit NS5A 
function. 
CyPA knockdown with RNA interference suppressed HCV infection, confirming that CsA blocks a 
critical function of CyPA itself, not a downstream effecter of the CsA-CyPA complex, as in the case of 
T cell suppression. In addition, the resistance to CsA was correlated with resistance to CyPA 
knockdown by shRNA  [25], further indicating that HCV susceptibility to CsA is mediated by CyPA. 
Of note, regardless of the mutations identified, all the CsA-resistant replicons isolated are still 
inhibited by CsA at high concentrations (>4 µM), suggesting that the resistance was a result of reduced 
dependence on CyP rather than of a complete independence. Strong support for this idea was first 
demonstrated in an experiment where a CsA-resistant replicon was treated with both a shRNA directed 
at CyPA and 0.5 µM of CsA, to either of which the replicon was normally resistant. The heightened 
sensitivity (i.e., disappearance of resistance) to the double treatment is best explained if the resistant Viruses 2010, 2                                       
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replicon still required CyP, albeit at a much lower level, to replicate  [25]. Conversely, overexpression 
of CyPA in replicon cells was shown to be correlated with reduced CsA sensitivity  [26]. 
Level of sensitivity to CsA treatment also appear to vary depending upon the genotypes or forms of 
viral genomes used in the in vitro studies. For example, a JFH-1 based replicon was less sensitive to 
CsA than were GT1b replicons  [69], and a chimeric replicon with JFH-1 NS5B inserted into a GT1b 
replicon backbone was more resistant to CsA treatment  [29]. These results may have implications for 
clinical-trial designs if natural polymorphism can affect the effectiveness of CPI therapy, although 
there is currently insufficient patient data to indicate that this would be the case. Full-length JFH-1 
virus has also been observed to be significantly (>100-fold) more sensitive to CsA and its derivatives 
than the corresponding NS3-NS5B subgenomic replicon. Two distinct, but not mutually exclusive, 
hypotheses have been proposed to explain this difference. Incorporation of NS2 into the subgenomic 
replicon may increase CsA sensitivity through an unidentified mechanism (no interaction between NS2 
and CyPA has been demonstrated), or CyPA may play a role in an additional step in the HCV life 
cycle (e.g., assembly) that cannot be measured in the replicon system  [26,28]. Interestingly, the NS5A 
mutations (D316E and Y317N) identified in the CsA-resistant full-length virus also conferred 
resistance in the NS3-NS5B and NS2-NS5B replicons, pointing to a role of NS5A as the “master 
regulator” of CsA susceptibility. 
6. Potential mechanism of resistance to CPIs 
How do mutations in the HCV genome confer reduced dependence on CyPA? Multiple 
mechanisms may be involved. The D316/320E and Y317/320N mutations in domain II of NS5A do 
not appear to alter the CsA sensitivity of the NS5A-CyPA interaction  [45,46,63]. They do, however, 
cause a conformation change at a putative CyPA substrate site that could either increase the 
isomerization efficiency of the surrounding prolines or render the structure more similar to the product 
of the isomerization  [63]. In either case, the mutant NS5A would require less CyPA to fold and/or 
function properly. A distinct set of NS5A mutations that is associated with CsA resistance has been 
identified by Kaul et al. to locate to the C-terminus of NS5A, near the cleavage site of the NS5A-5B 
precursor protein  [26]. These authors observed a correlation between a delay in NS5A-5B cleavage 
and CsA resistance for the mutations. It was then hypothesized that CyPA-binding by NS5A is only 
possible during a short window before or immediately after NS5A-5B cleavage, which normally 
occurs rapidly. Delay in NS5A-5B cleavage by mutations would then allow more time for CyPA-
binding, reducing CyPA dependence and conferring CsA-resistance. Finally, mutations in NS5B may 
increase the template-binding activity and RC incorporation of the polymerase, which probably 
depends on the efficient and proper folding of its viral cofactor, NS5A  [42,67]. Although no structural 
information is available regarding any of the putative complexes of CyPA-NS5A, CyPA-NS5B, or 
CyPA-NS5A-NS5B, all the data so far are consistent with a role of CyPA in the proper assembly and 
function of the HCV replicase complex  [42,70].  
7. Summary 
CyPA plays an indispensible role in the HCV life cycle, as evidenced by both chemical inhibition 
and genetic interference experiments in cell culture and in vivo. On the other hand, CyP inhibition Viruses 2010, 2                                       
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appears to have little effect on cell survival, and CyPA-knockout in mice was well tolerated  [71]. In 
addition, HCV resistance to CPIs appears to be relatively weak in vitro and rare in vivo. Accordingly, 
CPIs that lack immunosuppressive function hold promise as a new class of anti-HCV drugs that can be 
used either in combination with the current standard of care or with STAT-C therapies. 
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